TOP > 外国特許検索 > MARKER FOR UNDIFFERENTIATED MESENCHYMAL STEM CELLS AND USE THEREOF

MARKER FOR UNDIFFERENTIATED MESENCHYMAL STEM CELLS AND USE THEREOF UPDATE コモンズ

外国特許コード F160008911
整理番号 NU-668
掲載日 2016年12月1日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP071190
国際公開番号 WO 2017022472
国際出願日 平成28年7月19日(2016.7.19)
国際公開日 平成29年2月9日(2017.2.9)
優先権データ
  • JP2015153712 (2015.8.3) 15
発明の名称 (英語) MARKER FOR UNDIFFERENTIATED MESENCHYMAL STEM CELLS AND USE THEREOF UPDATE コモンズ
発明の概要(英語) The present invention addresses the problem of providing a marker molecule that is highly specific for mesenchymal stem cells in an undifferentiated state and enables identification of mesenchymal stem cells at a high sensitivity or preparation of highly pure mesenchymal stem cells. Provided are a marker for undifferentiated mesenchymal stem cells, said marker comprising immunoglobulin superfamily containing leucine-rich repeat, and a use of the same.
特許請求の範囲(英語) [claim1]
1. The leucine rich repeat content immunoglobulin super family (ISLR) it consists of, the not yet differentiation mesenchyme type trunk cell marker.
[claim2]
2. ISLR, includes each amino acid arrangement of the arrangement number 1-3, in claim 1 the not yet differentiation mesenchyme type trunk cell marker of statement.
[claim3]
3. From the cell population which includes the mesenchyme type trunk cell, the cell which reveals ISLR is sorted, the step which is collected is included, the method the not yet differentiation mesenchyme type trunk cell being manufactured.
[claim4]
4. The cell population which includes the mesenchyme type trunk cell, the marrow and the tooth medulla, adipose tissue and the uterus intima, the navel band, is derived from skeletal muscle or the peripheral blood, in claim 3 method of statement.
[claim5]
5. The method of featuring that it detects the revelation state of ISLR as index, detecting the not yet differentiation mesenchyme type trunk cell.
[claim6]
6. The step which inspects the revelation state of ISLR in the suffering inspection mesenchyme type trunk cell is included, the method not yet differentiation of the mesenchyme type trunk cell being appraised.
[claim7]
7. The mesenchyme type trunk cell is the human cell, either of the claim 3-6 in one section method of statement.
[claim8]
8. The anti- ISLR antibody is included, the reagent for not yet differentiation mesenchyme type trunk cell detection.
[claim9]
9. The reagent of statement is included in claim 8, the kit for not yet differentiation mesenchyme type trunk cell detection.
[claim10]
10. The method of detecting the not yet differentiation mesenchyme type trunk cell which features that it detects the revelation state of ISLR as index, accumulates to the affection region of the cancer or tissue conversion disease.
[claim11]
11. The cancer is the *** cancer, the colon cancer, or the breast cancer, the tissue conversion disease is the myocardial blockage, in claim 10 method of statement.
[claim12]
12. It consists of ISLR, the bio marker for convalescence presumption of cancer or tissue conversion disease.
[claim13]
13. The cancer is the *** cancer, the colon cancer, or the breast cancer, the tissue conversion disease is the myocardial blockage, in claim 12 the bio marker for convalescence presumption of statement.
[claim14]
14. The revelation quantity of ISLR was designated as index, convalescence presumption method of the cancer or tissue conversion diseased patient.
[claim15]
15. The cancer is the *** cancer, the colon cancer, or the breast cancer, the tissue conversion disease is the myocardial blockage, in claim 14 convalescence presumption method of statement.
[claim16]
16. The anti- ISLR antibody is included, the reagent for convalescence presumption of cancer or tissue conversion diseased patient.
[claim17]
17. The cancer is the *** cancer, the colon cancer, or the breast cancer, the tissue conversion disease is the myocardial blockage, in claim 16 the reagent for convalescence presumption of statement.
[claim18]
18. In claim the reagent of statement is included 16 or 17, the kit for convalescence presumption of cancer or tissue conversion diseased patient.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA UNIVERSITY
  • 発明者(英語)
  • ENOMOTO ATSUSHI
  • TAKAHASHI MASAHIDE
  • MAEDA KEIKO
  • HARA AKITOSHI
  • MIZUTANI YASUYUKI
国際特許分類(IPC)
指定国 (WO201722472)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close